Biosimilars – and the policy and regulatory debates surrounding these complex large-molecule drugs – continue to be a hot topic in Washington. A patent case in front of the Supreme Court and laws making their way through Congress have the potential to change the market and industry.
The Atlantic convened key stakeholders to discuss the state of and future for biosimilars. What impact will ongoing regulatory and policy considerations have? What can stakeholders expect when it comes to patents and exclusivity? And what effect will the priorities of leadership in Congress and the Administration have on the industry across the next few years?
Watch full session videos
- Wednesday, June 07
- 8:20 a.m.WelcomeEmily Akhtarzandi, Managing Director, AtlanticLIVE
Chester “Chip” Davis, Jr.*, President and CEO, Association for Accessible Medicines
- 8:30 a.m.The Role of CongressRepresentative Peter Welch (D-VT)
With Steve Clemons, Washington Editor at Large, The Atlantic
- 8:50 a.m.The Patent LandscapeBruce Artim, Senior Director, Federal Government Affairs, Eli Lilly and Company
Courtenay Brinckerhoff, Partner, Foley & Lardner LLP
Phil Nickson, Associate General Counsel, Intellectual Property, Momenta Pharmaceuticals
With Olga Khazan, Staff Writer, The Atlantic
- 9:20 a.m.Closing ThoughtsEmily Akhtarzandi, AtlanticLIVE
Also in This Series
The Next Drugs: The Future for Biosimilars
An Atlantic Policy Briefing
The Atlantic gathered key stakeholders to examine the future for biosimilars domestically and abroad.
The Next Drugs:
An Atlantic Policy Briefing on Biosimilars
The Atlantic will gather key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States.
Now in its 10th year, The Atlantic's Washington Ideas will tackle the most consequential issues of our time with some of the nation's most important leaders from business, politics and culture.